243 related articles for article (PubMed ID: 8478311)
1. In-vitro activity of dirithromycin in comparison with other new and established macrolides.
Bauernfeind A
J Antimicrob Chemother; 1993 Mar; 31 Suppl C():39-49. PubMed ID: 8478311
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activity of the new erythromycin derivative dirithromycin against gram-positive bacteria isolated from cancer patients.
Rolston KV; Ho DH; LeBlanc B; Bodey GP
Eur J Clin Microbiol Infect Dis; 1990 Jan; 9(1):30-3. PubMed ID: 2137413
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.
Hardy DJ; Hensey DM; Beyer JM; Vojtko C; McDonald EJ; Fernandes PB
Antimicrob Agents Chemother; 1988 Nov; 32(11):1710-9. PubMed ID: 3252753
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results.
Biedenbach DJ; Jones RN; Lewis MT; Croco MA; Barrett MS
Diagn Microbiol Infect Dis; 1999 Apr; 33(4):275-82. PubMed ID: 10212755
[TBL] [Abstract][Full Text] [Related]
5. Comparative in-vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organisms.
Williams JD; Maskell JP; Shain H; Chrysos G; Sefton AM; Fraser HY; Hardie JM
J Antimicrob Chemother; 1992 Jul; 30(1):27-37. PubMed ID: 1331019
[TBL] [Abstract][Full Text] [Related]
6. Dirithromycin: a new macrolide.
Wintermeyer SM; Abdel-Rahman SM; Nahata MC
Ann Pharmacother; 1996 Oct; 30(10):1141-9. PubMed ID: 8893122
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro potencies of nine new macrolides.
Fernandes PB; Hardy DJ
Drugs Exp Clin Res; 1988; 14(7):445-51. PubMed ID: 3240705
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin.
Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1997 Sep; 41(9):1867-70. PubMed ID: 9303375
[TBL] [Abstract][Full Text] [Related]
9. New drugs--reports of new drugs recently approved by the FDA. Dirithromycin.
Shinkai I; Ohta Y
Bioorg Med Chem; 1996 Apr; 4(4):521-2. PubMed ID: 8735838
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activity of A-56268.
Sefton AM; Maskell JP; Yong FJ; Chi SJ; Williams JD
Eur J Clin Microbiol Infect Dis; 1988 Dec; 7(6):798-802. PubMed ID: 2975218
[TBL] [Abstract][Full Text] [Related]
11. Activity of new macrolides against Bordetella pertussis and Bordetella parapertussis.
Hoppe JE; Eichhorn A
Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):653-4. PubMed ID: 2550234
[TBL] [Abstract][Full Text] [Related]
12. Review of macrolides and ketolides: focus on respiratory tract infections.
Zhanel GG; Dueck M; Hoban DJ; Vercaigne LM; Embil JM; Gin AS; Karlowsky JA
Drugs; 2001; 61(4):443-98. PubMed ID: 11324679
[TBL] [Abstract][Full Text] [Related]
13. The in vitro activity of some 14-, 15- and 16- membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum.
Felmingham D; Robbins MJ; Sanghrajka M; Leakey A; Ridgway GL
Drugs Exp Clin Res; 1991; 17(2):91-9. PubMed ID: 1650694
[TBL] [Abstract][Full Text] [Related]
14. Multi-centre collaborative study for the in vitro evaluation of new macrolides dirithromycin and erythromycylamine. Australian Group for Antimicrobial Resistance (AGAR).
Fernandes CJ; Benn RA; Nimmo GR
Pathology; 1995 Jan; 27(1):74-8. PubMed ID: 7603759
[TBL] [Abstract][Full Text] [Related]
15. [Macrolides. New therapeutic prospects].
Bryskier A; Labro MT
Presse Med; 1994 Dec; 23(38):1762-6. PubMed ID: 7831266
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of macrolides against gram-positive aerobes, Haemophilus influenzae, Moraxella catarrhalis and Bacteroides fragilis in Taiwan.
Wang FD; Liu IM; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Apr; 62(4):230-5. PubMed ID: 10367484
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial activity of rokitamycin compared with that of other macrolides.
Yu KW; Briones F; Chin NX; Neu HC
Diagn Microbiol Infect Dis; 1991; 14(4):331-5. PubMed ID: 1889182
[TBL] [Abstract][Full Text] [Related]
18. The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin.
Bahal N; Nahata MC
Ann Pharmacother; 1992 Jan; 26(1):46-55. PubMed ID: 1318761
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and antimicrobial evaluation of dirithromycin (AS-E 136; LY237216), a new macrolide antibiotic derived from erythromycin.
Counter FT; Ensminger PW; Preston DA; Wu CY; Greene JM; Felty-Duckworth AM; Paschal JW; Kirst HA
Antimicrob Agents Chemother; 1991 Jun; 35(6):1116-26. PubMed ID: 1929252
[TBL] [Abstract][Full Text] [Related]
20. Activity of azithromycin, clarithromycin, roxithromycin, dirithromycin, quinupristin/dalfopristin and erythromycin against Legionella species by intracellular susceptibility testing in HL-60 cells.
Stout JE; Arnold B; Yu VL
J Antimicrob Chemother; 1998 Feb; 41(2):289-91. PubMed ID: 9533475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
